Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionDividends Paid - CommonExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Mesa Laboratories (MLAB) Capital Expenditures (2016 - 2025)

Historic Capital Expenditures for Mesa Laboratories (MLAB) over the last 16 years, with Q4 2025 value amounting to $732000.0.

  • Mesa Laboratories' Capital Expenditures fell 996.31% to $732000.0 in Q4 2025 from the same period last year, while for Dec 2025 it was $3.6 million, marking a year-over-year decrease of 1085.18%. This contributed to the annual value of $4.2 million for FY2025, which is 6552.4% up from last year.
  • Latest data reveals that Mesa Laboratories reported Capital Expenditures of $732000.0 as of Q4 2025, which was down 996.31% from $1.1 million recorded in Q3 2025.
  • In the past 5 years, Mesa Laboratories' Capital Expenditures registered a high of $2.1 million during Q4 2021, and its lowest value of $225000.0 during Q2 2022.
  • Moreover, its 5-year median value for Capital Expenditures was $914500.0 (2021), whereas its average is $983150.0.
  • Its Capital Expenditures has fluctuated over the past 5 years, first soared by 73360.32% in 2021, then crashed by 6554.36% in 2022.
  • Mesa Laboratories' Capital Expenditures (Quarter) stood at $2.1 million in 2021, then fell by 19.67% to $1.7 million in 2022, then tumbled by 31.8% to $1.1 million in 2023, then dropped by 27.93% to $813000.0 in 2024, then fell by 9.96% to $732000.0 in 2025.
  • Its Capital Expenditures stands at $732000.0 for Q4 2025, versus $1.1 million for Q3 2025 and $1.0 million for Q2 2025.